Evodiamine inhibits the migration and invasion of nasopharyngeal carcinoma cells in vitro via repressing MMP-2 expression.

abstract：PURPOSE:Plitidepsin absorption, distribution, metabolism and excretion characteristics were investigated in a mass balance study, in which six patients received a 3-h intravenous infusion containing 7 mg 14C-plitidepsin with a maximum radioactivity of 100 µCi. METHODS:Blood samples were drawn and excreta were collecte...

journal_title：Cancer chemotherapy and pharmacology

authors： van Andel L,Rosing H,Tibben MM,Lucas L,Lubomirov R,Avilés P,Francesch A,Fudio S,Gebretensae A,Hillebrand MJX,Schellens JHM,Beijnen JH

更新日期：2018-09-01 00:00:00

abstract：PURPOSE:The efficacy and safety of a combined regimen of topotecan and etoposide was tested in patients with relapsed or refractory small-cell lung cancer. PATIENTS AND METHODS:From October 2003 to May 2005, 23 patients who have failed to the previous irinotecan and platinum chemotherapy received intravenous topotecan...

journal_title：Cancer chemotherapy and pharmacology

authors： Choi HJ,Cho BC,Shin SJ,Cheon SH,Jung JY,Chang J,Kim SK,Sohn JH,Kim JH

更新日期：2008-02-01 00:00:00

abstract：PURPOSE:Acute kidney injury (AKI) is a common and serious adverse effect of cisplatin-based chemotherapy. However, traditional markers of kidney function, such as serum creatinine, are suboptimal, because they are not sensitive measures of proximal tubular injury. We aimed to determine whether the new urinary biomarker...

journal_title：Cancer chemotherapy and pharmacology

authors： Shinke H,Masuda S,Togashi Y,Ikemi Y,Ozawa A,Sato T,Kim YH,Mishima M,Ichimura T,Bonventre JV,Matsubara K

更新日期：2015-11-01 00:00:00

abstract：BACKGROUND:Peritoneal surface malignancy resulting from local dissemination is a common manifestation of treatment failure of gastrointestinal cancers. Although the management of carcinomatosis has been improved with an aggressive surgical approach of extensive cytoreduction followed by heated intraoperative intraperit...

journal_title：Cancer chemotherapy and pharmacology

authors： Sugarbaker PH,Stuart OA

更新日期：2007-02-01 00:00:00

abstract：PURPOSE:By a scaffold shortening strategy, a small series of retinoidal amides fenretinide (4-HPR) analogs have been synthesized from α, β-ionones and tested for their antiproliferative and differentiating activities, and antioxidant effect. METHODS:The antiproliferative activity and triggering of apoptosis of our sho...

journal_title：Cancer chemotherapy and pharmacology

authors： Anzaldi M,Viale M,Macciò C,Castagnola P,Oliveri V,Rosano C,Balbi A

更新日期：2017-04-01 00:00:00

abstract：PURPOSE:BMS-310705, a novel semisynthetic derivative of epothilone B, is a tubulin-polymerization agent currently in phase I clinical trials for anticancer therapy. The in vitro and in vivo pharmacokinetics and oral bioavailability of BMS-310705 were investigated in mice, rats, and dogs. In addition, comparison of the ...

journal_title：Cancer chemotherapy and pharmacology

authors： Kamath AV,Chang M,Lee FY,Zhang Y,Marathe PH

更新日期：2005-08-01 00:00:00

abstract：PURPOSE:To evaluate the population pharmacokinetics of pemetrexed disodium in cancer patients enrolled in four different open-label, multicenter, nonrandomized phase II studies. METHODS:Pemetrexed disodium was administered as a 10-min intravenous infusion (600 mg/m2) every 21 days. A total of four blood samples were t...

journal_title：Cancer chemotherapy and pharmacology

authors： Ouellet D,Periclou AP,Johnson RD,Woodworth JR,Lalonde RL

更新日期：2000-01-01 00:00:00

abstract：:Modulators of protein kinase C (PKC) were used to investigate the role of this enzyme during Adriamycin-induced erythroid differentiation of K562 cells. Adriamycin (0.1 microM) induced erythroid differentiation in 60% +/- 10% of K562 cells. Phorbol myristate-12-acetate, an activator of protein kinase C, was strongly a...

journal_title：Cancer chemotherapy and pharmacology

authors： Hoffman R,Newlands ES

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:PF-00337210 is an oral, highly selective vascular endothelial growth factor receptor (VEGFR) inhibitor. We evaluated a composite of biomarkers in real time to identify the recommended phase 2 dose (RP2D) and preliminary anticancer activity of PF-00337210. PATIENTS AND METHODS:Patients (Pts) with advanced cance...

journal_title：Cancer chemotherapy and pharmacology

authors： Bruce JY,LoRusso PM,Goncalves PH,Heath EI,Sadowski E,Shalinsky DR,Zhang Y,Traynor AM,Breazna A,Ricart AD,Tortorici M,Liu G

更新日期：2016-03-01 00:00:00

abstract：:The interaction between cisplatin (cDDP) and tamoxifen (TAM) was evaluated in the human head and neck squamous-carcinoma cell lines UM-SCC-10B and UM-SCC-5. Synergy between cDDP and TAM was demonstrated in the UM-SCC-10B cell line. Concordant with the synergistic effect between cDDP and TAM, the rate of development of...

journal_title：Cancer chemotherapy and pharmacology

authors： Nakata B,Albright KD,Barton RM,Howell SB,Los G

更新日期：1995-01-01 00:00:00

abstract：:Axitinib is approved with indication in patients with advanced renal cell carcinoma (RCC). Due to the localization of this cancer, physicians sometimes have to deal with hemodialyzed patients. Data exploring hemodialysis (HD) impact on axitinib pharmacokinetic (PK) or safety are lacking. To date, no data have been pub...

journal_title：Cancer chemotherapy and pharmacology

authors： Thiery-Vuillemin A,Orillard E,Mouillet G,Calcagno F,Devillard N,Bouchet S,Royer B

更新日期：2017-06-01 00:00:00

abstract：PURPOSE:This phase I study assessed the safety, tolerability, maximum tolerated dose (MTD), pharmacokinetics, and preliminary antitumor effects of sunitinib combined with modified FOLFOX6 (mFOLFOX6). METHODS:Patients with advanced solid malignancies received mFOLFOX6 in 2-week cycles with escalating sunitinib doses (2...

journal_title：Cancer chemotherapy and pharmacology

authors： Leong S,Eckhardt SG,Chan E,Messersmith WA,Spratlin J,Camidge DR,Diab S,Khosravan R,Lin X,Chow Maneval E,Lockhart AC

更新日期：2012-07-01 00:00:00

abstract：PURPOSE:To evaluate the plasma and cerebrospinal fluid (CSF) pharmacokinetics and CSF penetration of tasidotin and metabolites in a nonhuman primate model. METHODS:Tasidotin 0.75 mg/kg was administered intravenously. The plasma and CSF concentrations of tasidotin and its metabolites were determined. Pharmacokinetic pa...

journal_title：Cancer chemotherapy and pharmacology

authors： Kilburn LB,Bonate PL,Blaney SM,McGuffey L,Nuchtern JG,Dauser R,Thompson P,Gibson BW,Berg SL

更新日期：2009-07-01 00:00:00

abstract：:The pharmakokinetic profiles of intraperitoneally infused platinum analogues were determined in 13 women exhibiting minimal residual disease following surgery and systemic chemotherapy for epithelial ovarian cancer or fallopian tube carcinoma by following the disposition of tracer doses of 195mPt radiolabel. Six patie...

journal_title：Cancer chemotherapy and pharmacology

authors： Lind MJ,Murphy DJ,Sharma H,Tinker N,Smith A,McAuliffe CA,Crowther D

更新日期：1991-01-01 00:00:00

abstract：PURPOSE:S-1 and gemcitabine (GS) combination therapy is a promising treatment for advanced biliary tract cancer (BTC). However, systemic administration of GS is associated with a high rate of grade 3 and 4 neutropenia. Hepatic arterial infusion (HAI) of gemcitabine may overcome this problem. We conducted a prospective ...

journal_title：Cancer chemotherapy and pharmacology

authors： Ishiwatari H,Hayashi T,Yoshida M,Ono M,Sato T,Miyanishi K,Sato Y,Takimoto R,Kobune M,Kato J

更新日期：2015-04-01 00:00:00

abstract：PURPOSE:Bevacizumab or temsirolimus regimens have clinical activity in the first-line treatment of advanced renal cell carcinoma (RCC). This phase I/II trial was conducted to determine the safety of combining both agents and its efficacy in RCC patients who progressed on at least one prior anti-VEGF receptor tyrosine k...

journal_title：Cancer chemotherapy and pharmacology

authors： Merchan JR,Qin R,Pitot H,Picus J,Liu G,Fitch T,Maples WJ,Flynn PJ,Fruth BF,Erlichman C

更新日期：2015-03-01 00:00:00

abstract：PURPOSE:Trifluorothymidine (TFT) is a fluoropyrimidine that is part of the novel combination metabolite TAS-102, in which TFT is combined with a potent thymidine phosphorylase inhibitor (TPI). TAS-102 is currently tested as an orally chemotherapeutic agent in different schedules in a phase I study. In its monophosphate...

journal_title：Cancer chemotherapy and pharmacology

authors： Temmink OH,Hoogeland MF,Fukushima M,Peters GJ

更新日期：2006-01-01 00:00:00

abstract：PURPOSE:A metronomic schedule of chemotherapy (resulting in a greater frequency of drug delivery) has shown efficacy in head and neck cancer. Our aim was to investigate the overall survival in tongue cancer patients with metronomic neoadjuvant chemotherapy with bleomycin compared to those with surgery alone. METHODS:I...

journal_title：Cancer chemotherapy and pharmacology

authors： Kina S,Nakasone T,Kinjo T,Maruyama T,Kawano T,Arasaki A

更新日期：2016-10-01 00:00:00

abstract：:A group of folate analogs of the 10-deaza-aminopterin series, which were designed on the basis of the results of an intensive biochemical and pharmacokinetic program, have been examined in therapy experiments utilizing a group of murine tumor models. These new analogs were found to be markedly superior to methotrexate...

journal_title：Cancer chemotherapy and pharmacology

authors： Sirotnak FM,DeGraw JI,Schmid FA,Goutas LJ,Moccio DM

更新日期：1984-01-01 00:00:00

abstract：:Physicochemical properties of two types of adriamycin preparation, suspensions and emulsions prepared for i.a. chemotherapy of hepatocellular carcinoma, were investigated. A suspension was prepared by dispersing adriamycin directly into the lipid contrast medium, Lipiodol, whereas an emulsion was obtained by emulsifyi...

journal_title：Cancer chemotherapy and pharmacology

authors： Katagiri Y,Mabuchi K,Itakura T,Naora K,Iwamoto K,Nozu Y,Hirai S,Ikeda N,Kawai T

更新日期：1989-01-01 00:00:00

abstract：:The cisplatin derivative TNO-6 was evaluated for clinical toxicity in a phase I trial. TNO-6 was given daily for 5 days every 3 weeks as a 30-min IV infusion without hydration. In all, 39 patients with advanced cancer were treated at doses of 2.5-9.0 mg/m2. No dose-limiting nephrotoxicity occurred, but evidence of mil...

journal_title：Cancer chemotherapy and pharmacology

authors： Sørensen JB,Groth S,Hansen SW,Nissen MH,Rørth M,Hansen HH

更新日期：1985-01-01 00:00:00

abstract：:To predict the clinical effect on leukemic disease of a combination regimen developed to circumvent multidrug resistance (MDR), we tested various antitumor agents in the presence and absence of AHC-52, a sensitizing agent for multidrug-resistant cells, in the i.v.-i.v. model of murine leukemia. In this model system, s...

journal_title：Cancer chemotherapy and pharmacology

authors： Shinoda H,Ebisu H,Mitsuhashi J,Inaba M,Tsuruo T

更新日期：1992-01-01 00:00:00

abstract：PURPOSE:Topotecan is widely used for refractory solid tumors but multi-drug resistance may occur due to tumor expression of ATP-binding cassette (ABC) transporters. Since erlotinib, an inhibitor of the epidermal growth factor receptor, also inhibits several ABC transporters, we performed a phase I study to evaluate the...

journal_title：Cancer chemotherapy and pharmacology

authors： Stewart CF,Tagen M,Schwartzberg LS,Blakely LJ,Tauer KW,Smiley LM

更新日期：2014-03-01 00:00:00

abstract：PURPOSE:To compare serum and urine levels of tamoxifen and metabolites after a loading dose and at the steady state. METHODS:A loading dose of 160 mg of tamoxifen was given to 14 patients with advanced breast cancer. Thereafter a regular daily dose of 30 mg of tamoxifen was given. Serum and urine levels of tamoxifen a...

journal_title：Cancer chemotherapy and pharmacology

authors： de Vos D,Slee PH,Briggs RJ,Stevenson D

更新日期：1998-01-01 00:00:00

abstract：PURPOSE:ASNA1 is homologous to E. coli ArsA, a well characterized ATPase involved in efflux of arsenite and antimonite. Cells resistant to arsenite and antimonite are cross-resistant to the chemotherapeutic drug cisplatin. ASNA1 is also an essential ATPase for the insertion of tail-anchored proteins into ER membranes a...

journal_title：Cancer chemotherapy and pharmacology

authors： Hemmingsson O,Zhang Y,Still M,Naredi P

更新日期：2009-02-01 00:00:00

abstract：:Cancer is a major health issue worldwide and the global burden of cancer is expected to reduce the costs of treatment as well as prolong the survival time. One of the promising approaches is drug repurposing, because it reduces costs and shortens the production cycle of research and development. Disulfiram (DSF), whic...

journal_title：Cancer chemotherapy and pharmacology

authors： Lu C,Li X,Ren Y,Zhang X

更新日期：2021-01-10 00:00:00

abstract：:We reviewed 139 resected patients with hepatocellular carcinoma at our clinic between 1963 and 1987, and using the 118 cases for the period between 1963 and 1986, we analyzed the prognostic factors that influenced the long-term prognosis by comparing the survival curves. Significant differences in the survival pattern...

journal_title：Cancer chemotherapy and pharmacology

authors： Kawano N,Ohmori Y,Inoue S,Nagao T,Morioka Y

更新日期：1989-01-01 00:00:00

abstract：BACKGROUND AND AIMS:oxaliplatin in combination with folinic acid (FA) and infusional 5-fluorouracil (5-FU) has shown significant anti-tumor activity in gastric cancer patients (FOLFOX). Previous studies have shown that gemcitabine (GEM), a new fluorinated anti-metabolite, enhances the individual anti-tumor activity of ...

journal_title：Cancer chemotherapy and pharmacology

authors： Correale P,Fulfaro F,Marsili S,Cicero G,Bajardi E,Intrivici C,Vuolo G,Carli AF,Caraglia M,Del Prete S,Greco E,Gebbia N,Francini G

更新日期：2005-12-01 00:00:00

abstract：PURPOSE:SU5416 is a novel small organic molecule that non-competitively inhibits the phosphorylation of the VEGF tyrosine kinase receptor, Flk-1. This phase IB study was performed to determine the safety, pharmacokinetics, and preliminary efficacy of the combination of SU5416 and paclitaxel in recurrent or metastatic c...

journal_title：Cancer chemotherapy and pharmacology

authors： Cooney MM,Tserng KY,Makar V,McPeak RJ,Ingalls ST,Dowlati A,Overmoyer B,McCrae K,Ksenich P,Lavertu P,Ivy P,Hoppel CL,Remick S

更新日期：2005-03-01 00:00:00

abstract：PURPOSE:Cyclophosphamide is one of the most frequently used agents in the neoadjuvant, adjuvant, and high-dose chemotherapeutic treatment of breast cancers. Preclinical models indicate that cellular sensitivity to cyclophosphamide and other oxazaphosphorines, e.g., ifosfamide, is inversely related to the cellular conte...

journal_title：Cancer chemotherapy and pharmacology

authors： Sreerama L,Sládek NE

更新日期：2001-03-01 00:00:00